Cardio Diagnostics Holdings, Inc. (CDIOW) stock

CDIOWNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as CDIO

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/30

$0.01+0.00 (0.00%)

Close on Oct 30, 2026Market cap $4.94MP/E –Yield –

Cardio Diagnostics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Cardio Diagnostics's price to sales ratio was 327.4× on Oct 19, 2026, against 350.3× a year earlier. Over the last 2 years it ranged from 132.8× to 437.2×, with a median of 326.8×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Oct 19, 2026	327.4×	+86.8
2025	Dec 31, 2025	240.6×	−17.8
2024	Nov 29, 2024	258.4×	–

Where these numbers come from

Parsed from the XBRL in Cardio Diagnostics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on May 13, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CDIOW.

Compare: CDIOW vs VRAX · CDIOW vs ADTX · CDIOW vs AWHL · CDIOW vs PRFX · CDIOW vs BDPT

Revenue growth-57.5% · median 310.0%

Operating margin-43737.5% · median -4059.4%

Net margin-43832.5% · median -5885.3%

Company	Revenue	Growth
AWHL	$170.00K	–
BDPT	$25.56K	+694.1%
CDIOW	$14.83K	-57.5%
ADTX	$14.34K	-74.1%
VRAX	–	–
PRFX	–	–

Company

Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
Fiscal year ends: December 31
Employees: 7
Auditor: Prager Metis CPAs, LLC
SEC CIK: 1870144

Advertisement
300 × 250

Cardio Diagnostics price to sales ratio

Price to Sales Ratio at the end of each year

More Cardio Diagnostics figures